Eva S Rodansky1, Laura A Johnson1, Sha Huang1, Jason R Spence2, Peter D R Higgins3. 1. Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 2. Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA; Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI, USA. 3. Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. Electronic address: phiggins@med.umich.edu.
Abstract
BACKGROUND & AIMS: Intestinal fibrosis is a critical complication of Crohn's disease (CD). Current in vitro models of intestinal fibrosis cannot model the complex intestinal architecture, while in vivo rodent models do not fully recapitulate human disease and have limited utility for large-scale screening. Here, we exploit recent advances in stem cell derived human intestinal organoids (HIOs) as a new human model of fibrosis in CD. METHODS: Human pluripotent stem cells were differentiated into HIOs. We identified myofibroblasts, the key effector cells of fibrosis, by immunofluorescence staining for alpha-smooth muscle actin (αSMA), vimentin, and desmin. We examined the fibrogenic response of HIOs by treatment with transforming growth factor beta (TGFβ) in the presence or absence of the anti-fibrotic drug spironolactone. Fibrotic response was assayed by expression of fibrogenic genes (COL1A1 (collagen, type I, alpha 1), ACTA2 (alpha smooth muscle actin), FN1 (fibronectin 1), MYLK (myosin light chain kinase), and MKL1 (megakaryoblastic leukemia (translocation) 1)) and proteins (αSMA). RESULTS: Immunofluorescent staining of organoids identified a population of myofibroblasts within the HIO mesenchyme. TGFβ stimulation of HIOs produced a dose-dependent pro-fibrotic response. Spironolactone treatment blocked the fibrogenic response of HIOs to TGFβ. CONCLUSIONS: HIOs contain myofibroblasts and respond to a pro-fibrotic stimulus in a manner that is consistent with isolated human myofibroblasts. HIOs are a promising model system that might bridge the gap between current in vitro and in vivo models of intestinal fibrosis in IBD.
BACKGROUND & AIMS:Intestinal fibrosis is a critical complication of Crohn's disease (CD). Current in vitro models of intestinal fibrosis cannot model the complex intestinal architecture, while in vivo rodent models do not fully recapitulate human disease and have limited utility for large-scale screening. Here, we exploit recent advances in stem cell derived human intestinal organoids (HIOs) as a new human model of fibrosis in CD. METHODS:Human pluripotent stem cells were differentiated into HIOs. We identified myofibroblasts, the key effector cells of fibrosis, by immunofluorescence staining for alpha-smooth muscle actin (αSMA), vimentin, and desmin. We examined the fibrogenic response of HIOs by treatment with transforming growth factor beta (TGFβ) in the presence or absence of the anti-fibrotic drug spironolactone. Fibrotic response was assayed by expression of fibrogenic genes (COL1A1 (collagen, type I, alpha 1), ACTA2 (alpha smooth muscle actin), FN1 (fibronectin 1), MYLK (myosin light chain kinase), and MKL1 (megakaryoblastic leukemia (translocation) 1)) and proteins (αSMA). RESULTS: Immunofluorescent staining of organoids identified a population of myofibroblasts within the HIO mesenchyme. TGFβ stimulation of HIOs produced a dose-dependent pro-fibrotic response. Spironolactone treatment blocked the fibrogenic response of HIOs to TGFβ. CONCLUSIONS: HIOs contain myofibroblasts and respond to a pro-fibrotic stimulus in a manner that is consistent with isolated human myofibroblasts. HIOs are a promising model system that might bridge the gap between current in vitro and in vivo models of intestinal fibrosis in IBD.
Authors: Jeffrey C Horowitz; Iyabode O Ajayi; Priya Kulasekaran; David S Rogers; Joshua B White; Sarah K Townsend; Eric S White; Richard S Nho; Peter D R Higgins; Steven K Huang; Thomas H Sisson Journal: Int J Biochem Cell Biol Date: 2011-10-25 Impact factor: 5.085
Authors: Laura A Johnson; Shail M Govani; Joel C Joyce; Akbar K Waljee; Brenda W Gillespie; Peter D R Higgins Journal: Inflamm Bowel Dis Date: 2011-11-13 Impact factor: 5.325
Authors: Laura A Johnson; Eva S Rodansky; Andrew J Haak; Scott D Larsen; Richard R Neubig; Peter D R Higgins Journal: Inflamm Bowel Dis Date: 2014-01 Impact factor: 5.325
Authors: Kang Kim; Laura A Johnson; Congxian Jia; Joel C Joyce; Sujal Rangwalla; Peter D R Higgins; Jonathan M Rubin Journal: Ultrasound Med Biol Date: 2008-02-21 Impact factor: 2.998
Authors: Guntram A Grassl; Yanet Valdez; Kirk S B Bergstrom; Bruce A Vallance; B Brett Finlay Journal: Gastroenterology Date: 2008-01-09 Impact factor: 22.682
Authors: Jason R Spence; Christopher N Mayhew; Scott A Rankin; Matthew F Kuhar; Jefferson E Vallance; Kathryn Tolle; Elizabeth E Hoskins; Vladimir V Kalinichenko; Susanne I Wells; Aaron M Zorn; Noah F Shroyer; James M Wells Journal: Nature Date: 2010-12-12 Impact factor: 49.962
Authors: Mahbubul H Shihan; Mallika Kanwar; Yan Wang; Erin E Jackson; Adam P Faranda; Melinda K Duncan Journal: Matrix Biol Date: 2020-03-12 Impact factor: 11.583
Authors: Qianhui Yu; Umut Kilik; Emily M Holloway; Yu-Hwai Tsai; Christoph Harmel; Angeline Wu; Joshua H Wu; Michael Czerwinski; Charlie J Childs; Zhisong He; Meghan M Capeling; Sha Huang; Ian A Glass; Peter D R Higgins; Barbara Treutlein; Jason R Spence; J Gray Camp Journal: Cell Date: 2021-05-20 Impact factor: 41.582
Authors: Markus Breunig; Jessica Merkle; Martin Wagner; Michael K Melzer; Thomas F E Barth; Thomas Engleitner; Johannes Krumm; Sandra Wiedenmann; Christian M Cohrs; Lukas Perkhofer; Gaurav Jain; Jana Krüger; Patrick C Hermann; Maximilian Schmid; Tamara Madácsy; Árpád Varga; Joscha Griger; Ninel Azoitei; Martin Müller; Oliver Wessely; Pamela G Robey; Sandra Heller; Zahra Dantes; Maximilian Reichert; Cagatay Günes; Christian Bolenz; Florian Kuhn; József Maléth; Stephan Speier; Stefan Liebau; Bence Sipos; Bernhard Kuster; Thomas Seufferlein; Roland Rad; Matthias Meier; Meike Hohwieler; Alexander Kleger Journal: Cell Stem Cell Date: 2021-04-28 Impact factor: 25.269
Authors: Laura A Johnson; Eva S Rodansky; Anhdao Tran; Stephen G Collins; Kathryn A Eaton; Benjamin Malamet; Calen A Steiner; Sha Huang; Jason R Spence; Peter D R Higgins Journal: Inflamm Bowel Dis Date: 2022-02-01 Impact factor: 7.290
Authors: Jie Wang; Sinan Lin; Jonathan Mark Brown; David van Wagoner; Claudio Fiocchi; Florian Rieder Journal: Immunol Rev Date: 2021-05-16 Impact factor: 10.983
Authors: Joseph Sleiman; Sara El Ouali; Taha Qazi; Benjamin Cohen; Scott R Steele; Mark E Baker; Florian Rieder Journal: Expert Rev Gastroenterol Hepatol Date: 2020-12-28 Impact factor: 3.869